Compliance & Validation — Documented
SOC 2 Type II, GDPR
AI protein engineering platform that designs and optimizes proteins with generative models, validated in an in-house wet lab.
Cradle Bio (Cradle Bio B.V.), founded in 2021 and headquartered in Amsterdam, Netherlands with offices in Zurich and Boston, provides a software platform for protein engineering: generative AI proposes sequence variants that a wet-lab loop validates before optimization. Its trust center documents a SOC 2 Type II report and GDPR compliance, and describes ISO 27001 as adopted/aligned rather than independently certified — request the certificate if ISO 27001 is a requirement. Engagement is a licensed software product rather than a discovery-services partnership.
64% — Partial coverage. Coverage score — how completely Atlas documents Cradle Bio across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.
SOC 2 Type II, GDPR
cloud
Ask the vendor: What is your pricing model, and what drives total cost of ownership?
Ask the vendor: What is a realistic implementation timeline, and what onboarding support is included?
Biotech Startup, Mid-Size Biotech, Large Pharma, Drug Discovery, R&D Leadership
Protein Structure Prediction
Series B, Founded 2021
Not captured in Atlas data — confirm directly. Excluded from the score above.
Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?
Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?